Maria Alba Dosil

Maria Alba Dosil

Auto-generated profile, based on publicly available information

Maria Alba Dosil

Authors' Affiliations: 1Oncologic Pathology Group, Dept. de Ciències Mèdiques Bàsiques, University of Lleida, Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, IRBLleida, Lleida; and 2Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Disease Models & Mechanisms
Verified
Journal Article
Open access
CMCristina Mirantes
Cristina Mirantes
NENúria Eritja
Núria Eritja
MDMaria Alba Dosil
Maria Alba Dosil
MSMaria Santacana
Maria Santacana
JPJudit Pallares
Judit Pallares
XDXavier Dolcet
Xavier Dolcet
Summary: PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. The role of PTEN in carcinogenesis has been validated by knockout mouse models. PTEN heterozygous mice develop neoplasms in multiple organs. Unfortunately, the embryonic lethality of biallelic excision of PTEN has inhibited the study of complete PTEN deletion in the development and progression of cancer. By crossing PTEN conditional knockout mice with transgenic mice expressing a tamoxifen-inducible Cre-ERT under the control of a chicken actin promoter, we have generated a tamoxifen-inducible mouse model that allows temporal control of PTEN deletion. Interestingly, administration of a single dose of tamoxifen resulted in PTEN deletion mainly in epithelial cells, but not in stromal, mesenchymal or hematopoietic cells. Using the mT/mG double-fluorescent Cre reporter mice, we demonstrate that epithelial-specific PTEN excision was caused by differential Cre activity among tissues and cells types. Tamoxifen-induced deletion of PTEN resulted in extremely rapid and consistent formation of endometrial in situ adenocarcinoma, prostate intraepithelial neoplasia and thyroid hyperplasia. We also analyzed the role of PTEN ablation in other epithelial cells, such as the tubular cells of the kidney, hepatocytes, colonic epithelial cells or bronchiolar epithelium, but those tissues did not exhibit neoplastic growth. Finally, to validate this model as a tool to assay the efficacy of anti-tumor drugs in PTEN deficiency, we administered the mTOR inhibitor everolimus to mice with induced PTEN deletion. Everolimus dramatically reduced the progression of endometrial proliferations and significantly reduced thyroid hyperplasia. This model could be a valuable tool to study the cell-autonomous mechanisms involved in PTEN-loss-induced carcinogenesis and provides a good platform to study the effect of anti-neoplastic drugs on PTEN-negative tumors.

1 July 2013 in The American Journal of Pathology
Verified
Journal Article
Closed access
NENuria Eritja
Nuria Eritja
CMCristina Mirantes
Cristina Mirantes
DLDavid Llobet-Navas
David Llobet-Navas
AYAndree Yeramian
Andree Yeramian
LBLaura Bergadà
Laura Bergadà
XDXavier Dolcet
Xavier Dolcet

1 April 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
NENuria Eritja
Nuria Eritja
MDMónica Domingo
Mónica Domingo
MDMaria Alba Dosil
Maria Alba Dosil
CMCristina Mirantes
Cristina Mirantes
MSMaria Santacana
Maria Santacana
XDXavier Dolcet
Xavier Dolcet
Mutations in fibroblast growth factor receptor 2 (FGFR2) have been recently described as a molecular-specific feature in endometrial carcinomas and the presence of activated FGFR2 mutations is associated with poor prognosis. For that reason, inhibition of FGFR2 could be a therapeutic target in the treatment of endometriod carcinomas. In this work, we investigated the antitumoral activity of dovitinib (a multiple kinase inhibitor) in human endometrial cancer cell (ECC) lines. We found that dovitinib caused cell growth arrest, loss of clonogenic growth, and cell-cycle arrest in FGFR2-mutated ECCs in in vitro and in vivo experiments. Next, we investigated the mechanistic basis of dovitinib effects. We could determine that dovitinib modified expression levels of well-known key cell-cycle regulatory proteins that induce cellular senescence. To further investigate the role of dovitinib, we analyzed its effect on estrogen receptor α (ER-α) expression. Surprisingly, we discovered that dovitinib enhances ER-α expression in FGFR2-mutant ECCs. Because blocking one signaling pathway is often not sufficient to cause total tumor regression and the effectiveness of individual inhibitors is often short-lived, we examined the impact of targeting FGFR2 with dovitinib in combination with a selective ER antagonist, fulvestrant (ICI182.780). Combination of dovitinib plus ICI182.780 resulted in a significantly higher inhibition of cell growth than dovitinib treatment alone. These findings suggest that combinatory therapies using dovitinib plus ICI182.780 treatment can be truly effective in patients with endometrial carcinomas carrying FGFR2 mutations. Mol Cancer Ther; 13(4); 776–87. ©2014 AACR.

3 April 2023
Verified
Other
Open access
NENúria Eritja
Núria Eritja
MDMónica Domingo
Mónica Domingo
MDMaria Alba Dosil
Maria Alba Dosil
CMCristina Mirantes
Cristina Mirantes
MSMaria Santacana
Maria Santacana
XDXavier Dolcet
Xavier Dolcet

3 April 2023
Verified
Other
Open access
NENúria Eritja
Núria Eritja
MDMónica Domingo
Mónica Domingo
MDMaria Alba Dosil
Maria Alba Dosil
CMCristina Mirantes
Cristina Mirantes
MSMaria Santacana
Maria Santacana
XDXavier Dolcet
Xavier Dolcet

3 April 2023
Verified
Other
Open access
NENúria Eritja
Núria Eritja
MDMónica Domingo
Mónica Domingo
MDMaria Alba Dosil
Maria Alba Dosil
CMCristina Mirantes
Cristina Mirantes
MSMaria Santacana
Maria Santacana
XDXavier Dolcet
Xavier Dolcet